Clinical Trials Logo

Urethral Stricture clinical trials

View clinical trials related to Urethral Stricture.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06192654 Enrolling by invitation - Clinical trials for Urethral Stricture, Male

Small Intestinal Submucosa Graft for Repair of Anterior Urethral Strictures

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

The field of research for this study is tissue engineering and the utilization of a small intestinal submucosa graft as a substitute biomaterial for conventional buccal mucosa in substitution urethroplasty of anterior urethral strictures.

NCT ID: NCT03205670 Enrolling by invitation - Urethral Stricture Clinical Trials

Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers

Start date: June 1, 2017
Phase: Early Phase 1
Study type: Interventional

This study investigates safety and efficacy of surgical treatment of patients with anterior urethral stricture using a tissue-engineered construct based on autologous buccal mucosa cells and matrix from reconstituted collagen and reinforcing polylactoglycolide fibers. This is a single arm study with no control. Success will be assessed via objective and subjective methods; complications will be tallied in a standardized fashion. Outcomes will be measured at five years.

NCT ID: NCT01889888 Enrolling by invitation - Clinical trials for Urethral Strictures in Males

Effectiveness and Safety of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc)from a portion of the fat harvested from the patient's front abdominal wall. ADRC will be administered one-time endoscopically into submucosal layer of urethra under eye control into the stricture site after mechanical dilation. This is a single arm study with no control. All patients receive cell therapy.